RA
ESPR

Royce & Associates’s Esperion Therapeutics ESPR Stock Holding History

Royce & Associates’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,626,995
Closed -$7.2M – 781
2026
Q1 		$7.2M Sell
2,626,995
-974,528
-27% -$3.09M 0.07% 405
2025
Q4 		$13.3M Buy
3,601,523
+1,308,035
+57% +$4.23M 0.14% 231
2025
Q3 		$6.08M Buy
+2,293,488
New +$4.44M 0.06% 429

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Royce & Associates's ESPR Position: Q2 2026 in Review

Royce & Associates sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 2,626,995 shares — an estimated $7.2M sold.

Royce & Associates first reported a position in ESPR in Q3 2025 and held it in 3 quarters. The position peaked at $13.3M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Royce & Associates reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Royce & Associates sold 2,626,995 Esperion Therapeutics shares in Q2 2026, an estimated $7.2M.
  • Royce & Associates first reported a position in Esperion Therapeutics in Q3 2025 and held it in 3 quarters.
  • Royce & Associates's Esperion Therapeutics position peaked at $13.3M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.